Home/ Stocks/ ADTX

Aditxt, Inc. Common Stock

ADTX XNAS

$0.97 -0.09 (-7.88%) ▼ 15-min delayed

Open

$1.06

High

$1.10

Low

$0.93

Volume

149.0K

Market Cap

$559.3K

About Aditxt, Inc. Common Stock

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 26 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$748	$-24,207,669	$-548.78
Q2 2025	$1.0K	$-7,395,658	$-3.45
Q1 2025	$1.0K	$-5,952,465	$-8.12
FY 2024	$134.0K	$-35,020,058	$-3062.51

Earnings & Analyst Ratings

Next Earnings: Wed, May 13, 2026

Calendar →

Related Market News

No specific coverage for ADTX yet. Check out our latest market news or earnings calendar.

Get ADTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Aditxt, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.